+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
GODAVARI GODAVARI

Godavari Drugs Share Price

₹105.00 +5 (5%)
50.65% Gain from 52W Low

14 Aug, 2026 4:01 PM (IST)

Godavari Drugs live price: ₹105.00. It opened at ₹100 vs previous close ₹100; intraday high/low: ₹105/₹98. The 50 & 200 DMA stand at ₹113.00/₹104.90.

Godavari Drugs Performance

  • Today's Low
  • ₹98
  • Today's High
  • ₹105
  • 52 Week Low
  • ₹70
  • 52 Week High
  • ₹135
  • Open Price₹100
  • Previous Close₹100
  • Volume5,996
  • 50 DMA₹113.00
  • 100 DMA₹111.20
  • 200 DMA₹104.90

Godavari Drugs Chart

Investment Returns

  • Over 1 Month -14.56%
  • Over 3 Month -17.32%
  • Over 6 Month + 20.33%
  • Over 1 Year + 23.14%

Smart Investing Starts Here Start SIP with Godavari Drugs for Steady Growth!

Invest Now

Godavari Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.6
  • PEG Ratio
  • 2.6
  • Market Cap Cr
  • 106
  • P/B Ratio
  • 1.4
  • Average True Range
  • 5.3
  • EPS
  • 4.1
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.5
  • RSI
  • 41.69
  • MFI
  • 18.36

Latest Stock News Updates

Godavari Drugs Ltd - 530317 - Announcement under Regulation 30 (LODR)-Allotment

Board of Directors of the Company in its meeting held on Friday, 14th August, 2026 at 11.45 A.M. approved and passed the resolution for allotment of Equity Shares on conversion of 7,86,690 Equity Shares at an issue price of Rs.89/- each to Promoters Category on Preferential Basis

Godavari Drugs Ltd - 530317 - Submission Of Un-Audited Standalone Financial Results For The Quarter Ended As On June 30, 2026

Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026

Godavari Drugs Ltd - 530317 - Board Meeting Outcome for Outcome Of Board Meeting Held On 14.08.2026

Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026 and Allotment of Equity Shares on conversion of 7,86,690 (Seven Lakhs Eighty-Six Thousand Six Hundred and Ninety Only) warrants into 7,86,690 (Seven Lakhs Eighty-Six Thousand Six Hundred and Ninety Only) Equity Shares at an issue price of Rs. 89/- each (including a premium of Rs. 10/- each), to 'Promoters Category', on preferential basis

Godavari Drugs Financials

Godavari Drugs Technicals

EMA & SMA

Current Price
₹105.00
+ 5 (5%)
pointer
  • Bearish Moving Average 10
  • Bullish Moving Average 6
  • 20 Day
  • ₹108.00
  • 50 Day
  • ₹113.00
  • 100 Day
  • ₹111.20
  • 200 Day
  • ₹104.90

Resistance and Support

102.7 Pivot Speed
  • R3 114.20
  • R2 109.60
  • R1 107.30
  • S1 100.40
  • S2 95.80
  • S3 93.50

Godavari Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-14 Quarterly Results
2026-05-27 Audited Results
2026-02-11 Quarterly Results
2026-01-15 Preferential issue of shares
2025-11-14 Quarterly Results

Godavari Drugs Shareholding Pattern

57.04%
40.23%
1.48%
1.26%

About Godavari Drugs

Godavari Drugs engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and its intermediates through its manufacturing facility at Nanded, Maharashtra, India. View More
  • NSE Symbol
  • GODAVARI
  • BSE Symbol
  • 530317
  • Executive Director,Managing Director,Chief Executive Officer
  • Mukund Kakani
  • ISIN
  • INE362C01012

Similar Stocks to Godavari Drugs

Godavari Drugs FAQs

Godavari Drugs share price is ₹105 As on 16 August, 2026 | 03:36

The Market Cap of Godavari Drugs is ₹106.3 Cr As on 16 August, 2026 | 03:36

The P/E ratio of Godavari Drugs is 25.6 As on 16 August, 2026 | 03:36

The PB ratio of Godavari Drugs is 1.4 As on 16 August, 2026 | 03:36

The 52 week High & Low of Godavari Drugs is ₹135.2/₹69.7 respectively As on 16 August, 2026 | 03:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23